Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-26T15:10:52.214Z Has data issue: false hasContentIssue false

Risk Factors for Vancomycin-Resistant Enterococcus (VRE) Infection in Colonized Patients With Cancer

Published online by Cambridge University Press:  02 January 2015

Rola Husni
Affiliation:
University of Texas M.D. Anderson Cancer Center, Department of Infectious Diseases, Infection Control and Employee Health, Houston, Texas
Ray Hachem
Affiliation:
University of Texas M.D. Anderson Cancer Center, Department of Infectious Diseases, Infection Control and Employee Health, Houston, Texas
Hend Hanna
Affiliation:
University of Texas M.D. Anderson Cancer Center, Department of Infectious Diseases, Infection Control and Employee Health, Houston, Texas
Issam Raad*
Affiliation:
University of Texas M.D. Anderson Cancer Center, Department of Infectious Diseases, Infection Control and Employee Health, Houston, Texas
*
The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 402, Houston, TX 77030

Abstract

To determine the risk factors for vancomycin-resistant Enterococcus (VRE) infection in colonized patients with cancer, we conducted a case–control study. According to multivariate analysis, the only significant factors were neutropenia (< 500 cells/mm3) for more than 1 week and the use of oral vancomycin. Therefore, colonized neutropenic patients with cancer who have previously used oral vancomycin are most prone to VRE infection.

Type
Concise Communications
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Cohen, ML. Antimicrobial resistance: prognosis for public health. Trends Microbiol 1994;2:422425.Google Scholar
2.Edmond, MB, Ober, JF, Dawson, JD, Weinbaum, DL, Wenzel, RP. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996;23:12341239.Google Scholar
3.Kuehnert, MJ, Jernigan, JA, Jarvis, WR, et al. Association between mucositis severity and vancomycin-resistant enterococcal bloodstream infection in hospitalized cancer patients. Infect Control Hosp Epidemiol 1999;20:660663.Google Scholar
4 Tornieporth, NG, Roberts, RB, John, J, Hafner, A, Riley, LW. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis 1996;23:767772.CrossRefGoogle ScholarPubMed
5.Edmond, MD, Ober, JF, Weinbaum, DL, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995;20:126133.Google Scholar
6.Shay, DK, Maloney, SA, Montecalvo, M, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995;172:9931000.Google Scholar
7.Dever, LL, Smith, SM, Handwerker, S, Eng, RHK. Vancomycin-dependent Enterococcus faecium isolated from stool following oral vancomycin therapy. J Clin Microbiol 1995;33:27702773.Google Scholar
8.Green, M, Shlaes, JH, Barbadora, K, Shlaes, DM. Bacteremia due to vancomycin-dependent Enterococcus faecium. Clin Infect Dis 1995;20:712714.Google Scholar
9.Donskey, CJ, Chowdhry, TK, Hecker, MT, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000;343:19251932.Google Scholar
10.Roghmann, M-C, McCarter, RJ, Brewrink, J, Cross, AS, Morris, JG. Clostridium difficile infection is a risk factor for bacteremia due to vancomycin-resistant enterococci (VRE) in VRE-colonized patients with acute leukemia. Clin Infect Dis 1997;25:10561059.Google Scholar